Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer

David S Alberts, Dava Garcia-Kendall, Earl A. Surwit

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Following cisplatin combination chemotherapy for advanced epithelial type ovarian cancer, response to subsequent treatments has proved relatively poor. Mitomycin C and 5-fluorouracil (5-FU) have both been reported to have useful activity as single agents in patients with drug-refractory ovarian cancer. We have carried out a phase II trial of a combination of these two agents in 25 patients who had previously received a median of two chemotherapy regimens (range, one to five regimens). Patients received mitomycin C, 10 mg/m2 intravenously (IV) on day 1 every 6 weeks, and 5-FU, 500 mg/m2 IV daily on days 1 to 3 every 3 weeks. Four patients experienced a complete response and six patients a partial response, for an overall objective response rate of 40%. The median duration of complete and partial responses was 8 and 4 months, respectively. The median duration of survival for all 25 patients was 10.5 months (range, 2.5 to 49+ months). The most prevalent toxicity was bone marrow suppression. Leukopenia occurred in 68% of the patients, and 36% experienced thrombocytopenia. Severe or life-threatening bone marrow suppression was observed in 36% of the patients and required dose reduction or drug discontinuance in 28% and 24%, respectively. We conclude that mitomycin C plus 5-FU combination therapy appears to be extremely active in patients with drug-refractory disease. Confirmatory trials are indicated.

Original languageEnglish (US)
Pages (from-to)22-26
Number of pages5
JournalSeminars in Oncology
Volume15
Issue number3 SUPPL. 4
StatePublished - 1988

Fingerprint

Mitomycin
Fluorouracil
Ovarian Neoplasms
Pharmaceutical Preparations
Therapeutics
Bone Marrow
Leukopenia
Proxy
Combination Drug Therapy
Thrombocytopenia
Cisplatin
Drug Therapy
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer. / Alberts, David S; Garcia-Kendall, Dava; Surwit, Earl A.

In: Seminars in Oncology, Vol. 15, No. 3 SUPPL. 4, 1988, p. 22-26.

Research output: Contribution to journalArticle

Alberts, David S ; Garcia-Kendall, Dava ; Surwit, Earl A. / Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer. In: Seminars in Oncology. 1988 ; Vol. 15, No. 3 SUPPL. 4. pp. 22-26.
@article{bd97c0e5d4f44e5692c77fba978fe526,
title = "Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer",
abstract = "Following cisplatin combination chemotherapy for advanced epithelial type ovarian cancer, response to subsequent treatments has proved relatively poor. Mitomycin C and 5-fluorouracil (5-FU) have both been reported to have useful activity as single agents in patients with drug-refractory ovarian cancer. We have carried out a phase II trial of a combination of these two agents in 25 patients who had previously received a median of two chemotherapy regimens (range, one to five regimens). Patients received mitomycin C, 10 mg/m2 intravenously (IV) on day 1 every 6 weeks, and 5-FU, 500 mg/m2 IV daily on days 1 to 3 every 3 weeks. Four patients experienced a complete response and six patients a partial response, for an overall objective response rate of 40{\%}. The median duration of complete and partial responses was 8 and 4 months, respectively. The median duration of survival for all 25 patients was 10.5 months (range, 2.5 to 49+ months). The most prevalent toxicity was bone marrow suppression. Leukopenia occurred in 68{\%} of the patients, and 36{\%} experienced thrombocytopenia. Severe or life-threatening bone marrow suppression was observed in 36{\%} of the patients and required dose reduction or drug discontinuance in 28{\%} and 24{\%}, respectively. We conclude that mitomycin C plus 5-FU combination therapy appears to be extremely active in patients with drug-refractory disease. Confirmatory trials are indicated.",
author = "Alberts, {David S} and Dava Garcia-Kendall and Surwit, {Earl A.}",
year = "1988",
language = "English (US)",
volume = "15",
pages = "22--26",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 4",

}

TY - JOUR

T1 - Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer

AU - Alberts, David S

AU - Garcia-Kendall, Dava

AU - Surwit, Earl A.

PY - 1988

Y1 - 1988

N2 - Following cisplatin combination chemotherapy for advanced epithelial type ovarian cancer, response to subsequent treatments has proved relatively poor. Mitomycin C and 5-fluorouracil (5-FU) have both been reported to have useful activity as single agents in patients with drug-refractory ovarian cancer. We have carried out a phase II trial of a combination of these two agents in 25 patients who had previously received a median of two chemotherapy regimens (range, one to five regimens). Patients received mitomycin C, 10 mg/m2 intravenously (IV) on day 1 every 6 weeks, and 5-FU, 500 mg/m2 IV daily on days 1 to 3 every 3 weeks. Four patients experienced a complete response and six patients a partial response, for an overall objective response rate of 40%. The median duration of complete and partial responses was 8 and 4 months, respectively. The median duration of survival for all 25 patients was 10.5 months (range, 2.5 to 49+ months). The most prevalent toxicity was bone marrow suppression. Leukopenia occurred in 68% of the patients, and 36% experienced thrombocytopenia. Severe or life-threatening bone marrow suppression was observed in 36% of the patients and required dose reduction or drug discontinuance in 28% and 24%, respectively. We conclude that mitomycin C plus 5-FU combination therapy appears to be extremely active in patients with drug-refractory disease. Confirmatory trials are indicated.

AB - Following cisplatin combination chemotherapy for advanced epithelial type ovarian cancer, response to subsequent treatments has proved relatively poor. Mitomycin C and 5-fluorouracil (5-FU) have both been reported to have useful activity as single agents in patients with drug-refractory ovarian cancer. We have carried out a phase II trial of a combination of these two agents in 25 patients who had previously received a median of two chemotherapy regimens (range, one to five regimens). Patients received mitomycin C, 10 mg/m2 intravenously (IV) on day 1 every 6 weeks, and 5-FU, 500 mg/m2 IV daily on days 1 to 3 every 3 weeks. Four patients experienced a complete response and six patients a partial response, for an overall objective response rate of 40%. The median duration of complete and partial responses was 8 and 4 months, respectively. The median duration of survival for all 25 patients was 10.5 months (range, 2.5 to 49+ months). The most prevalent toxicity was bone marrow suppression. Leukopenia occurred in 68% of the patients, and 36% experienced thrombocytopenia. Severe or life-threatening bone marrow suppression was observed in 36% of the patients and required dose reduction or drug discontinuance in 28% and 24%, respectively. We conclude that mitomycin C plus 5-FU combination therapy appears to be extremely active in patients with drug-refractory disease. Confirmatory trials are indicated.

UR - http://www.scopus.com/inward/record.url?scp=0023723058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023723058&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 22

EP - 26

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 4

ER -